e-Drug3D
465
METYROSINE
INN
METYROSINE
cas 672-87-7
CLASS
ANTIHYPERTENSIVE
TREATMENT OF PHEOCHROMOCYTOMA (TUMOR OF THE ADRENAL GLAND)
DECREASES ENDOGENOUS LEVELS OF CATECHOLAMINES
ROUTE (list)
ORAL
ATC code
C02KB01
PK parameters
F 69 PERCENT
t1/2 3.3 HOUR
Solubility
VERY SLIGHTLY SOLUBLE IN WATER
TARGET TYROSINE HYDROXYLASE
Tyrosine 3-monooxygenase UNIPROT P07101 TH
Formula:
C10H13NO3
Calculated chemical properties:
MW 194.21
NB_atoms 14
XLogP -0.60
PSA 79.112
NB_HD 3
NB_HA 4
fsp3 0.30
Lipinski(0=no;1=yes) 1
NB_atoms 14
XLogP -0.60
PSA 79.112
NB_HD 3
NB_HA 4
fsp3 0.30
Lipinski(0=no;1=yes) 1
FDA
NDA 017871 (pdf not found) INN (METYROSINE) DEMSER (BAUSCH) APPROVAL= AP YEAR= 1979 NEWMOLECULARENTITY
NDA 213734 (pdf not found) INN (METYROSINE) METYROSINE (AMNEAL) APPROVAL= AP YEAR= 2020
NDA 215541 (pdf not found) INN (METYROSINE) METYROSINE (LEADING) APPROVAL= AP YEAR= 2024
NDA 218620 (pdf not found) INN (METYROSINE) METYROSINE (DR REDDYS LABS SA) APPROVAL= AP YEAR= 2025
NDA 017871 (pdf not found) INN (METYROSINE) DEMSER (BAUSCH) APPROVAL= AP YEAR= 1979 NEWMOLECULARENTITY
NDA 213734 (pdf not found) INN (METYROSINE) METYROSINE (AMNEAL) APPROVAL= AP YEAR= 2020
NDA 215541 (pdf not found) INN (METYROSINE) METYROSINE (LEADING) APPROVAL= AP YEAR= 2024
NDA 218620 (pdf not found) INN (METYROSINE) METYROSINE (DR REDDYS LABS SA) APPROVAL= AP YEAR= 2025